Document is current
Any future updates will be listed below
-
Authors
Pralong, Anne https://orcid.org/0000-0001-8201-2344
Simon, Steffen T. https://orcid.org/0000-0002-6884-1813
Herling, Marco https://orcid.org/0000-0001-7473-7476
Reimer, Alinda https://orcid.org/0000-0003-1618-8784
Schoerger, Berenike https://orcid.org/0000-0002-4209-6659
Pusch, Lisa https://orcid.org/0009-0002-2463-8845
Scheid, Christoph https://orcid.org/0009-0007-6539-226X
Hallek, Michael https://orcid.org/0000-0002-7425-4455
Weliwitage, Jithmi https://orcid.org/0009-0000-6596-6680
Hellmich, Martin https://orcid.org/0000-0001-5174-928X
Voltz, Raymond https://orcid.org/0000-0002-4761-3395
Holtick, Udo https://orcid.org/0000-0002-5543-0257
-
Funding
Funding for this research was provided by:
Deutsche José Carreras Leukämie-Stiftung (DJCLS)
- License Information
-
More Information
Article History
Received: 12 March 2026
Revised: 17 March 2026
Accepted: 14 April 2026
First Online: 27 April 2026
Competing interests
: The authors declare no competing interests.
: This study was approved by the Ethics Commission of the Faculty of Medicine of the University of Cologne on 23 March 2022 (20-1370_2). It followed the ethical principles of the Declaration of Helsinki and its amendments. Informed consent was obtained from all participants when opening the survey link.
: This survey is part of the research program “Allo-PaS” (Palliative-Supportive Management in Allogeneic Stem Cell Transplantation), registration number: DRKS00027290, German Clinical Trials Register, .
